{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:48:04Z","timestamp":1777279684004,"version":"3.51.4"},"reference-count":38,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biopharmaceutical Statistics"],"DOI":"10.1080\/10543406.2026.2663451","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:55:53Z","timestamp":1777276553000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Mind the gap: Bayesian equipoise calibration of clinical trial designs"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-3019","authenticated-orcid":false,"given":"Fabio","family":"Rigat","sequence":"first","affiliation":[{"name":"AstraZeneca Oncology Biometrics","place":["Cambridge, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041833"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-017-0189-z"},{"issue":"2","key":"e_1_3_5_4_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.2517-6161.1979.tb01066.x","article-title":"Reference posterior distributions for Bayesian inference","volume":"41","author":"Bernardo JM.","year":"1979","unstructured":"Bernardo JM. 1979. Reference posterior distributions for Bayesian inference. J Retailing R Stat Soc Ser B. 41(2):113\u2013128. https:\/\/academic.oup.com\/jrsssb\/article\/41\/2\/113\/7027630","journal-title":"J Retailing R Stat Soc Ser B"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1201\/EBK1439825488"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad030"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_11_1","unstructured":"FDA Oncologic Drugs Advisory Committee Meeting. 2023. Sotorasib for KRAS G12C mutated locally advanced or metastatic NSCLC. https:\/\/www.fda.gov\/media\/172756\/download"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae042"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/14777509221121107"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707163170304"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1214\/09-STS284D"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-65052-4_4"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.1644"},{"key":"e_1_3_5_18_1","unstructured":"ICH E11A. 2024. Paediatric extrapolation. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E11A_Guideline_Step4_2024_0821.pdf"},{"key":"e_1_3_5_19_1","unstructured":"ICH E20. 2024. Adaptive clinical trials working group. https:\/\/database.ich.org\/sites\/default\/files\/E20_FinalConceptPaper_2019_1107_0.pdf"},{"key":"e_1_3_5_20_1","unstructured":"ICH E22. 2024. General considerations for patience preference studies working group. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E22_ConceptPaper_2024_0602.pdf"},{"key":"e_1_3_5_21_1","unstructured":"ICH E9. 1998. Statistical principles for clinical trials CPMP\/ICH\/363\/96. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf"},{"key":"e_1_3_5_22_1","unstructured":"ICH E9 (R1). 2020. Addendum on estimands and sensitivity analysis in clinical trials EMA\/CHMP\/ICH\/436221\/2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf"},{"key":"e_1_3_5_23_1","unstructured":"ICH guideline E8 (R1). 2022. On general considerations for clinical studies. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-8-general-considerations-clinical-trials-step-5_en.pdf"},{"issue":"3","key":"e_1_3_5_24_1","first-page":"227","article-title":"Prior probabilities","volume":"4","author":"Jaynes ET","year":"1968","unstructured":"Jaynes ET. 1968. Prior probabilities. IEEE Trans Syst Man Cybern Syst Sci Cybern. 4(3):227\u2013241. https:\/\/ieeexplore.ieee.org\/document\/4082152","journal-title":"IEEE Trans Syst Man Cybern Syst Sci Cybern"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511790423"},{"key":"e_1_3_5_26_1","volume-title":"Theory of probability","author":"Jeffreys H","year":"1961","unstructured":"Jeffreys H. 1961. Theory of probability. Oxford University Press. ISBN: 9780198503682."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780367805326"},{"issue":"1","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jme.17.1.30","article-title":"At what level of collective equipoise does a clinical trial become ethical?","volume":"17","author":"Johnson N","year":"1991","unstructured":"Johnson N, Lilford RJ, Brazier W. 1991. At what level of collective equipoise does a clinical trial become ethical? J Med Ethics. 17(1):30\u201334. https:\/\/pubmed.ncbi.nlm.nih.gov\/2033628\/","journal-title":"J Med Ethics"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-017-07522-z"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-70578-7"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.175"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907"},{"issue":"10","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018\u00a0haematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker U","year":"2019","unstructured":"Platzbecker U et al. 2019. Proposals for revised IWG 2018\u00a0haematological response criteria in patients with MDS included in clinical trials. Blood. 133(10):1020\u20131030. https:\/\/pubmed.ncbi.nlm.nih.gov\/30404811\/","journal-title":"Blood"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5916"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2339"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.10136"},{"key":"e_1_3_5_37_1","doi-asserted-by":"crossref","first-page":"113503","DOI":"10.1016\/j.ejca.2023.113503","article-title":"Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies","volume":"198","author":"Shahnam A","year":"2023","unstructured":"Shahnam A et al. 2023. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies. Eur J Cancer Feb. 198:113503. https:\/\/pubmed.ncbi.nlm.nih.gov\/38134560\/","journal-title":"Eur J Cancer Feb"},{"issue":"4","key":"e_1_3_5_38_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jclinepi.2009.06.003","article-title":"Methods to elicit beliefs for Bayesian priors: A systematic review","volume":"63","author":"Sindhu RJ","year":"2010","unstructured":"Sindhu RJ et al. 2010. Methods to elicit beliefs for Bayesian priors: A systematic review. J Educ Chang Clin Epidemiol. 63(4):355\u2013369. https:\/\/pubmed.ncbi.nlm.nih.gov\/19716263\/","journal-title":"J Educ Chang Clin Epidemiol"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-32562-0"}],"container-title":["Journal of Biopharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10543406.2026.2663451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:56:03Z","timestamp":1777276563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10543406.2026.2663451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":38,"alternative-id":["10.1080\/10543406.2026.2663451"],"URL":"https:\/\/doi.org\/10.1080\/10543406.2026.2663451","relation":{},"ISSN":["1054-3406","1520-5711"],"issn-type":[{"value":"1054-3406","type":"print"},{"value":"1520-5711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=lbps20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=lbps20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}